Incyte Corporation (INCY)

[surf1944]

7:01AM Incyte: FDA accepts NDA filing for Ruxolitinib as a treatment for Myelofibrosis (INCY) 16.24 : Co announced FDA has accepted for filing the New Drug Application for Incyte's lead investigational compound, ruxolitinib, as a potential treatment for patients with myelofibrosis. The FDA also has granted Incyte's request for Priority Review, which is given to investigational drugs that may offer either a major advance in treatment or provide a treatment where no adequate therapy exists. If the application is approved, Co anticipates that ruxolitinib could be available for US patients with MF in the fourth quarter of 2011.